Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 8/20 | 0.51 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PTP4A3 | O75365 | 2/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.32 |
| ▸ | PPARD | Q03181 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL630626 | 0.87 | PTPN1 (0.51) | PTPN1CTSLCTSBPTP4A3FFAR1 | |
| SCHEMBL629669 | 0.85 | PTPN1 (0.49) | PTPN1PTGER1FFAR1PPARD | |
| SCHEMBL629847 | 0.83 | PTPN1 (0.49) | PTPN1FFAR1PPARDMGLL | |
| SCHEMBL629597 | 0.83 | PTPN1 (0.47) | PTPN1FFAR1PPARD | |
| SCHEMBL3005189 | 0.82 | PTPN1 (0.48) | PTPN1PTPN2 | |
| SCHEMBL629774 | 0.81 | PTPN1 (0.51) | PTPN1PTPN2 | |
| Potassium SCHEMBL629775 | 0.81 | PTPN1 (0.51) | PTPN1PTPN2 | |
| SCHEMBL2998204 | 0.81 | PTPN1 (0.61) | PTPN1CTSLCTSBPTPN2 | |
| Potassium SCHEMBL2998210 | 0.81 | PTPN1 (0.61) | PTPN1CTSLCTSBPTPN2 | |
| SCHEMBL629591 | 0.81 | PTPN1 (0.46) | PTPN1CTSLCTSBPTP4A3CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963292-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-7700633-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| US-20080262050-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | disclosed |
| EP-1963292-A2 | ORGANIC COMPOUNDS | Novartis Pharma AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007067615-A2 | THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262050-A1 | Organic Compounds | PTPRS, PTPRO, PTPRC | PTPN1 23/4885PTGER1 1095/4885CTSL 3599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.